TY - JOUR T1 - Joint EANM, SNMMI and IAEA Enabling Guide: How to Set Up a Theranostics Centre JF - Journal of Nuclear Medicine JO - J Nucl Med DO - 10.2967/jnumed.122.264321 SP - jnumed.122.264321 AU - Ken Herrmann AU - Luca Giovanella AU - Andrea Santos AU - Jonathan Gear AU - Pinar Ozgen Kiratli AU - Jens Kurth AU - Ana M. Denis-Bacelar AU - Roland Hustinx AU - Marianne Patt AU - Richard L. Wahl AU - Diana Paez AU - Francesco Giammarile AU - Hossein Jadvar AU - Neeta Pandit-Taskar AU - Munir Ghesani AU - Jolanta Kunikowska Y1 - 2022/04/01 UR - http://jnm.snmjournals.org/content/early/2022/04/21/jnumed.122.264321.abstract N2 - The theranostics concept using the same target for both imaging and therapy dates back to the middle of the last century, when radioactive iodine was first used to treat thyroid diseases. Since then, radioiodine has become broadly established clinically for diagnostic imaging and therapy of benign and malignant thyroid disease, worldwide. However, only since the approval of SSTR2-targeting theranostics following the NETTER-1 trial in neuroendocrine tumours, and the positive outcome of the VISION trial has theranostics gained substantial attention beyond nuclear medicine. The roll-out of radioligand therapy for treating a high-incidence tumour such as prostate cancer requires the expansion of existing, and the establishment of new theranostics centres. Despite wide global variation in the regulatory, financial and medical landscapes, this guide attempts to provide valuable information to enable interested stakeholders to safely initiate and operate theranostic centres. This enabling guide does not intend to answer all possible questions, but rather to serve as an overarching framework for multiple, more detailed future initiatives. It recognizes that there are regional differences in the specifics of regulation of radiation safety, but common elements of best practice valid globally. ER -